Published in AIDS Res Hum Retroviruses on October 10, 1998
Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 2.45
Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest (2002) 1.46
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis (2005) 1.26
Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.97
Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 0.88
Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1. Antimicrob Agents Chemother (2010) 0.86
In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J Virol (2006) 0.85
Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells. J Virol (2014) 0.84
α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS One (2012) 0.83
Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J Infect Dis (2010) 0.83
Cell-associated transmission of HIV type 1 and other lentiviruses in small-animal models. J Infect Dis (2014) 0.82
Differential selection of specific human immunodeficiency virus type 1/JC499 variants after mucosal and parenteral inoculation of chimpanzees. J Virol (2002) 0.78
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science (2001) 10.93
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med (1998) 4.92
HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA. EMBO J (1989) 4.73
Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol (1990) 4.38
Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science (1984) 4.02
The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol (1996) 3.82
RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell (2001) 3.80
Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A (1986) 3.76
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 3.61
Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature (1990) 3.54
Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet (1985) 3.27
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 3.22
Visualization of melanosome dynamics within wild-type and dilute melanocytes suggests a paradigm for myosin V function In vivo. J Cell Biol (1998) 3.21
Directed assembly of one-dimensional nanostructures into functional networks. Science (2001) 3.21
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20
Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J (1994) 3.19
Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (1987) 2.82
Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol (1986) 2.65
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res (2001) 2.37
Myosin V associates with melanosomes in mouse melanocytes: evidence that myosin V is an organelle motor. J Cell Sci (1997) 2.24
Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23
Molecular cloning of lymphadenopathy-associated virus. Nature (1985) 2.22
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
Inactivation of lymphadenopathy associated virus by chemical disinfectants. Lancet (1984) 2.19
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Vet Immunol Immunopathol (1989) 2.09
Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst (2001) 2.06
Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine (2000) 1.97
Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol (2001) 1.96
Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science (1984) 1.95
High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol (1993) 1.93
Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene (1989) 1.83
A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology (1993) 1.83
Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res (1986) 1.83
Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene (2006) 1.82
Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses (2001) 1.77
Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS. Science (1984) 1.73
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol (1994) 1.72
The natural history of infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type III. Ann Intern Med (1985) 1.71
Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science (1992) 1.71
A distinct African lentivirus from Sykes' monkeys. J Virol (1993) 1.58
Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol (1993) 1.57
Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state. N Engl J Med (1984) 1.51
Genetic susceptibility to tobacco carcinogenesis. Cancer Invest (1999) 1.48
Should South Africa be preparing for HIV-1 vaccine efficacy trials? S Afr Med J (1997) 1.40
Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology (1998) 1.39
Components of saliva inactivate human immunodeficiency virus. Lancet (1986) 1.39
Vaginal transmission of human immunodeficiency virus (HIV) to a chimpanzee. J Infect Dis (1986) 1.38
Myelopathy in a patient dually infected with HIV-1 and HTLV-I. S Afr Med J (1992) 1.38
Isolation from African Sykes' monkeys (Cercopithecus mitis) of a lentivirus related to human and simian immunodeficiency viruses. J Virol (1991) 1.38
Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer (2000) 1.37
Diagnostic value of serum gamma-glutamyl transferase isoenzyme for hepatocellular carcinoma: a 10-year study. Am J Gastroenterol (1992) 1.37
Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci U S A (1986) 1.36
Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (1992) 1.36
Strong strain hardening in nanocrystalline nickel. Phys Rev Lett (2009) 1.34
Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur J Biochem (1990) 1.33
Direct inhibition of G(1) cdk kinase activity by MyoD promotes myoblast cell cycle withdrawal and terminal differentiation. EMBO J (1999) 1.33
Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS (1997) 1.33
Thymic cortical epithelium is sufficient for the development of mature T cells in relB-deficient mice. J Immunol (1997) 1.33
Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. EMBO J (1999) 1.32
SIV from stump-tailed macaques: molecular characterization of a highly transmissible primate lentivirus. Virology (1992) 1.29
Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg (1994) 1.29
Viral load in tissues during the early and chronic phase of non-pathogenic SIVagm infection. J Med Primatol (2004) 1.29
Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res (2001) 1.29
Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. AIDS Res Hum Retroviruses (1992) 1.28
Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev (1998) 1.28
Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis (2000) 1.26
Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis (1999) 1.25
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine (1999) 1.25
XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis (2000) 1.25
Wild-type isopropylmalate isomerase in Salmonella typhimurium is composed of two different subunits. J Bacteriol (1981) 1.24
Lift-off PMN-PT Thick Film for High Frequency Ultrasonic Biomicroscopy. J Am Ceram Soc (2010) 1.24
An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res (2001) 1.21
Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France. Clin Exp Immunol (2007) 1.19
Rift Valley fever virus: a seroepidemiologic study of small terrestrial vertebrates in South Africa. Am J Trop Med Hyg (1997) 1.17
Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses (1992) 1.17
Transfusion-acquired, autochthonous human babesiosis in Japan: isolation of Babesia microti-like parasites with hu-RBC-SCID mice. J Clin Microbiol (2000) 1.15
Early pathogenesis of disease caused by SIVsmmPBj14 molecular clone 1.9 in macaques. AIDS Res Hum Retroviruses (1993) 1.14
Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene (2007) 1.13
Myosin Va associates with microtubule-rich domains in both interphase and dividing cells. Cell Motil Cytoskeleton (1998) 1.13
HLA-B27 polymorphism in patients with juvenile and adult-onset ankylosing spondylitis in Southern China. Tissue Antigens (2010) 1.13
HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS (2000) 1.12
A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol (1991) 1.12
Transmission of lymphadenopathy-associated virus/human T lymphotropic virus type III in sexual partners. Seropositivity does not predict infectivity in all cases. Am J Med (1986) 1.11
The evolutionary rate of nonpathogenic simian immunodeficiency virus (SIVagm) is in agreement with a rapid and continuous replication in vivo. Virology (1996) 1.11
Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells. J Virol Methods (1987) 1.11
Mucosal immune system of the human genital tract. J Infect Dis (1999) 1.10